总金额有望超20亿美元！加科思药业与阿斯利康就泛KRAS抑制剂达成全球独家许可协议

Core Insights - The collaboration between 加科思-B (01167.HK) and AstraZeneca focuses on the development and commercialization of the Pan-KRAS inhibitor JAB-23E73, with AstraZeneca obtaining exclusive rights outside of China [1] - 加科思 will receive an upfront payment of $100 million and is eligible for up to $1.915 billion in milestone payments, along with tiered royalties on net sales outside of China [1] - The partnership aims to enhance 加科思's global pipeline and influence in the oncology innovation ecosystem, providing necessary funding for key clinical projects [2] Group 1 - 加科思 has entered into a collaboration agreement with AstraZeneca for the Pan-KRAS inhibitor JAB-23E73, which will be co-developed and commercialized in China [1] - The agreement includes a $100 million upfront payment and potential milestone payments totaling up to $1.915 billion, along with royalties on net sales outside of China [1] - JAB-23E73 targets multiple KRAS mutation subtypes and is currently undergoing Phase I clinical trials in China and the U.S., showing early signs of anti-tumor activity [1] Group 2 - The collaboration is expected to accelerate 加科思's global pipeline strategy and enhance its impact in the global oncology innovation ecosystem [2] - The upfront payment will provide additional funding support for 加科思's key clinical projects, facilitating faster development of innovative therapies [2] - 加科思 plans to continue focusing on KRAS and STING signaling pathways to expedite the delivery of milestone therapies to patients [2]